While diversity in clinical trials has won attention in recent years, uneven representation of diverse populations in clinical trials remains a core barrier to global healthcare equity. Real-world data (RWD) paired with artificial intelligence techniques can almost instantly analyze how well drugs work in diverse subpopulations once they hit the market. RWD can also help…

The complexity of patient records, with their mix of unstructured notes and diverse data types, defies traditional analysis. While a thorough review of even a single patient’s file can be tedious  for a human, AI tools offer the power to analyze tens or even hundreds of millions of records, unlocking data patterns that would otherwise…

In episode 3 of AI Meets Life Sci, DeviceTalks Managing Editor Kayleen Brown and Pharma and Biotech Editor Brian Buntz sit down with GE HealthCare GM of Oncology Ben Newton and Haley Schwartz of Catalyze Healthcare to discuss the impacts of AI to screen, diagnose, prognose, and treat cure disease while addressing real-world implementation issues from regulation and liability to clinician trust and adoption. They review the AI…

The value of artificial intelligence (AI) and machine learning (ML) in medical imaging is undeniable: more accurate diagnoses, predictive insights and streamlined workflows. However, as Big Pharma and medical research institutions amplify their AI and ML endeavors, they confront pivotal challenges. Chief among these challenges are the intricacies of labeling and annotating medical images. Approximately…

In episode 2 of AI Meets Life Sci, DeviceTalks Managing Editor Kayleen Brown, and Pharma Editor Brian Buntz explore how Big Tech is developing artificial intelligence (AI) infrastructure in a variety of healthcare organizations. Elena Bonfiglioli, global business leader for Health and Life Sciences at Microsoft, weighs in on the subject, also sharing that she…

In drug discovery and development, generative AI and natural-language processing (NLP) tools promise more than incremental productivity gains. For companies that can integrate such tools strategically into their workflows, the tools open the door to a fundamental rethinking of operational processes. For instance, generative AI tools can accelerate drafting of research articles, novel target identification,…

The White House has released an executive order that contains what it hails as “the most sweeping actions ever taken to protect Americans from the potential risks of AI systems.” Relevant to drug development, a fact sheet on the order describes its aim to help further “the responsible use of AI in healthcare and the…

Insilico Medicine, an AI-based biotech startup, announced details of their first AI-designed drug candidate to enter human clinical trials. INS018_055 is an experimental treatment for idiopathic pulmonary fibrosis, a rare lung disease. Through their Insilico AI-driven drug discovery platform, they discovered and designed INS018_055 in just 30 months, significantly faster than the industry average. Phase…

The development of new drugs is undeniably a data-intensive endeavor. Despite impressive advances in AI over the past years, researchers often continue to grapple with crushing data volumes. This hurdle is particularly apparent in clinical trials, where crucial data is often stored in machine-unfriendly formats such as PDFs, PowerPoint or HTML or other formats. This article explores…

Imagine a world where the process of developing life-saving drugs is as streamlined as a modern assembly line. In such a reality, generative AI in drug discovery might churn out promising compounds with similar efficiency and precision as a factory robot assembling a car. Moreover, such technology could chip away at the steep cost and…

The year 2020 was a watershed moment for many reasons, but notably, it cast a light on the pervasive health and social inequities that have long marred the U.S. The COVID-19 pandemic hit diverse populations disproportionately hard, as Deloitte and others have noted. Additionally, the tragic deaths of George Floyd, Breonna Taylor and others provoked…

Machine learning algorithms, such as Alphabet’s neural network-based model AlphaFold2, are steadily transforming medical research, shedding light on complex biological structures. A recent case in point involves research using the technology to explore the Commander complex, a 16-protein complex crucial for cellular protein transport processes. This complex is not only vital for normal cellular function,…

“Can we treat chronic inflammation in ulcerative colitis by reversing immune cell activation in colonic mucosa?” That’s an example of a biological question that the AI-enabled drug discovery firm BenevolentAI (AMS:BAI) would ask when exploring a new drug target. Incorporating a disease, sign, mechanism and tissue into a single question provides focal points for the…